Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Dysplasix Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Dysplasix: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Eltanexor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Eltanexor: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Zeltiprone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Zeltiprone: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
TG-01(Targovax) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
TG-01(Targovax): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Resomelagon Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Resomelagon: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Sulanemadlin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Sulanemadlin: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Beiqi Yifei Tablets Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Beiqi Yifei Tablets: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ZYY-742 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
ZYY-742: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
NBIP-1435 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
NBIP-1435: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
NNC0638-0355 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
NNC0638-0355: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ORAL-LYO-FMT Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
ORAL-LYO-FMT: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
WAS123 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
WAS123: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.